CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of myelodysplastic syndromes.
  
  LEARNING OBJECTIVES

  • Recognize the value of molecular testing for patients with myelodysplastic syndromes (MDS), and determine how various genetic alterations may affect MDS classification and risk assessment.
  • Evaluate the importance of age, performance status, cytogenetic profile and other patient- and disease-related factors in the selection and sequencing of therapy for lower- and higher-risk MDS.
  • Recognize the recent FDA approval of the combination of decitabine and cedazuridine for intermediate- and high-risk MDS, and identify patients for whom treatment with this novel approach may be appropriate.
  • Describe the biologic rationale for and available research findings with venetoclax in combination with azacitidine for patients with high-risk MDS, and appraise the potential role of this strategy in current and future clinical care.
  • Develop an understanding of the mechanisms of action of and available data with other emerging combination approaches for higher-risk MDS to prepare for their potential availability in routine practice.
  • Implement a plan to manage the side effects associated with approved and investigational therapies for MDS to support quality of life and continuation of treatment.
  • Recollect the designs of ongoing clinical trials for low- and high-risk MDS, and counsel appropriate patients about the potential benefits of participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Rami Komrokji, MD
  Senior Member and Section Head for Leukemia and MDS
  Vice Chair, Department of Malignant Hematology
  Moffitt Cancer Center
  Professor of Oncologic Sciences
  Morsani College of Medicine, University of South Florida
  Tampa, Florida
  
  Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, CTI BioPharma Corp, Genentech, a member of the Roche Group, Gilead Sciences Inc, Innovent, Novartis, PharmaEssentia, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, Acceleron Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Geron, Jazz Pharmaceuticals Inc, Novartis; Speakers Bureau: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Jazz Pharmaceuticals Inc, Servier Pharmaceuticals LLC; Other: Incyte Corporation (Judging Panel MPN Heroes 2021/MPN Award Winner 2020).
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Gilead Sciences Inc and Taiho Oncology Inc.
  
  Release date: April 2022
  Expiration date: April 2023